Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Katisko, Kaspera | Kokkonen, Ninab; c | Krüger, Johannac; d | Hartikainen, Päivia; e | Koivisto, Anne M.a; e | Helisalmi, Seppoa | Korhonen, Ville E.g | Kokki, Merjah | Tuusa, Jussib; c | Herukka, Sanna-Kaisaa; e | Solje, Einoa; e | Haapasalo, Annakaisaf | Tasanen, Kaisab; c | Remes, Anne M.a; c; d; e; *
Correspondence: [*] Correspondence to: Anne M. Remes, Professor, MD, PhD, Unit of Clinical Neuroscience, Neurology, University of Oulu, P.O. Aapistie 7, FI 90014, Oulu, Finland. Tel.: +358 505330090; E-mail: anne.remes@oulu.fi.
Abstract: Recent studies have shown an epidemiological and immunological association between bullous pemphigoid (BP) and several neurological or psychiatric diseases. Here, our aim was for the first time to specify whether an association exists between BP and frontotemporal lobar degeneration (FTLD). Medical histories of FTLD patients (N = 196) were screened for clinical comorbidity, and BP180 and BP230 autoantibodies were analyzed in the sera of FTLD patients (N = 70, including 24 C9orf72 repeat expansion carriers) by BP180-NC16A-ELISA and BP230-ELISA. One FTLD patient (C9orf72 repeat expansion carrier) had a comorbid diagnosis of BP. Increased levels of serum BP180 autoantibodies (cutoff value >9 U/ml) were detected more often in FTLD patients (10.0%) than in controls (4.9%). Moreover, elevated levels of both BP180 and BP230 autoantibodies were found more often in C9orf72 repeat expansion-carrying FTLD than non-carrying patients or controls. However, none of these differences reached a statistical significance likely due to our limited cohort size. In conclusion, our findings suggest that subset of FTLD patients especially with the C9orf72 repeat expansion may have an immunological association with BP.
Keywords: Autoantibody, bullous pemphigoid, C9orf72 , comorbidity, dementia, frontotemporal dementia, immunology
DOI: 10.3233/JAD-180624
Journal: Journal of Alzheimer's Disease, vol. 66, no. 2, pp. 743-750, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl